Alkaliptosis: a new weapon for cancer therapy

Cancer Gene Ther. 2020 May;27(5):267-269. doi: 10.1038/s41417-019-0134-6. Epub 2019 Aug 30.

Abstract

Malignant tumors are one of the major causes of death worldwide, and the development of better treatments is urgently needed. There are many types of cancer treatment, such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy, that might improve patient outcomes in a genotype- and stage-dependent manner. The main goal of cancer therapy is to inhibit biological capabilities of tumors and eventually eliminate the cancer cells. However, cancer cells are well known to escape apoptosis, a form of programmed cell death that was first described in studies of cell development and tissue remodelling. Increasing our understanding of cell death may result in new anticancer approaches that target types of nonapoptotic cell death, such as necroptosis, ferroptosis, autophagy-dependent cell death, and alkaliptosis. Notably, alkaliptosis, a pH-dependent form of regulated cell death, has been recently identified as a new strategy for cancer therapy across multiple tumor types, especially in pancreatic cancer.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoquinolines / pharmacology*
  • Aminoquinolines / therapeutic use
  • Antigens, Neoplasm / metabolism
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Benzamides / pharmacology*
  • Benzamides / therapeutic use
  • Carbonic Anhydrase IX / metabolism
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Down-Regulation / drug effects
  • Drug Development
  • Humans
  • Hydrogen-Ion Concentration / drug effects*
  • NF-kappa B / metabolism
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Regulated Cell Death / drug effects*
  • Signal Transduction / drug effects

Substances

  • Aminoquinolines
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Benzamides
  • N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide
  • NF-kappa B
  • CA9 protein, human
  • Carbonic Anhydrase IX